Please login to the form below

Not currently logged in

Eli Lilly drug discovery initiative

Open collaboration between Eli Lilly and global laboratory researchers is the goal of the new Lilly Phenotypic Drug Discovery Initiative, known as PD2

Open collaboration between Eli Lilly and global laboratory researchers is the goal of the new Lilly Phenotypic Drug Discovery Initiative, known as PD2.

Through the venture, Alzheimer's disease, cancer, diabetes and osteoporosis will be targeted.

The scheme will use Lilly's disease-state assays and a secure web portal to evaluate the therapeutic potential of compounds synthesized in university and biotechnology laboratories. Its findings could ultimately form the basis for collaboration or licensing agreements between Lilly and external institutions.

"Each year, researchers throughout the world design and synthesize compounds in university and biotechnology laboratories that are never fully evaluated as potential drug candidates," said Alan D Palkowitz, vice president of discovery chemistry research and technologies at Lilly. "There's an untapped source of ideas and compounds in the greater scientific community that could ultimately impact patients' lives following further evaluation and development."

Such collaborations are not new, but PD2 aims to provide global external researchers with easier access to Lilly's drug discovery and development process, particularly for groups that may not have worked with Lilly before.

Through PD2, researchers confidentially submit a structure of their compound for initial computational evaluation using proprietary Lilly algorithms focused on drug-like properties and structural novelty. If the compound structure meets certain criteria, the researcher is then invited to submit a physical sample for biological testing. All testing by Lilly is free, and all intellectual property rights remain with the submitting researcher and/or institution at this stage.

After biological testing, Lilly provides the external researchers with a data report comprising a complete biological profile of the compound across the four assay modules. In return, Lilly has first rights to exclusively negotiate a collaboration or licensing agreement for promising compounds.

17th June 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...